Key facts
- This page summarizes Karen Firestone's Form 4 filing for Amylyx Pharmaceuticals, Inc. (AMLX).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 26 May 2026, 16:00.
Karen Firestone - 21 May 2026 Form 4 Insider Report for Amylyx Pharmaceuticals, Inc. (AMLX)
- Reporting relationship
- Director
- Issuer ticker
- AMLX
- Reported as of
- 21 May 2026
- Net transaction value
- +$51,338
- SEC form
- 4
- Accepted by SEC
- 26 May 2026, 16:00:07 UTC
- Prior SEC filing
- 23 Dec 2025
- Next SEC filing
- 08 Jun 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Joshua B. Cohen, as Attorney in Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Karen Firestone filed Form 4 for Amylyx Pharmaceuticals, Inc. (AMLX) on 26 May 2026.
Change
- Previous filing in this sequence was filed on 23 Dec 2025.
- Current net transaction value: +$51,338.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001969821
Primary reporting owner
Firestone Karen
- Relationship
- Director
- Address
- C/O AMYLYX PHARMACEUTICALS, INC., 55 CAMBRIDGE PARKWAY, SUITE 6W, CAMBRIDGE
- Signature
- /s/ Joshua B. Cohen, as Attorney in Fact
- Signature date
- 26 May 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
AMLX
transaction
Common Stock
Purchase
- Transaction value
- $51,338
- Shares
- +3,800
- Change %
- +6%
- Price
- $13.51
- Shares after
- 66,900
- Date
- 21 May 2026
- Ownership
- Direct
* marks a reported price that did not pass the local price check.